Continuous Bioprocessing of Recombinant Insulin: Comparative Yield and Purity Analysis

Authors

  • Baumann F Department of Bioprocess Engineering, University of Hamburg, Hamburg, Germany Author
  • Jankauskas E Department of Biotechnology, Lithuanian University of Health Sciences, Kaunas, Lithuania Author
  • Marchand J Department of Analytical Chemistry, Sorbonne University, Paris, France Author

DOI:

https://doi.org/10.5281/zenodo.22638282

Keywords:

recombinant insulin, continuous bioprocessing, perfusion cell culture, continuous chromatography, downstream purification

Abstract

Background: Recombinant insulin has been manufactured by batch and fed-batch fermentation since the 1980s, but rising
demand and cost pressure have prompted interest in continuous bioprocessing. Objective: This narrative review synthesizes
published evidence comparing continuous and batch/fed-batch upstream cultivation and downstream purification for
recombinant insulin and related recombinant proteins. Methods: Peer-reviewed studies on E. coli and Pichia pastoris insulin
fermentation, continuous chromatography (periodic countercurrent, countercurrent tangential chromatography), and perfusion
cell culture were identified and individually verified, with titre, yield, and purity data extracted. Findings: Optimized fed-batch E.
coli processes achieve gram-per-litre insulin titres with purity exceeding 98-99% after multi-step polishing, while continuous
chromatography platforms validated for antibodies and adapted for insulin purification achieve comparable or modestly
improved step yields and purity at higher throughput per resin volume. Perfusion culture sustains substantially higher
volumetric productivity than fed-batch in analogous biologics. Conclusions: Continuous operations can match or exceed batch
yield and purity for insulin manufacturing, though head-to-head insulin-specific comparative studies remain scarce relative to
the antibody literature.

References

Goeddel DV, Kleid DG, Bolivar F, Heyneker HL, Yansura DG, Crea R, Hirose T, Kraszewski A, Itakura K, Riggs AD (1979). Expression in Escherichia coli of chemically synthesized genes for human insulin. Proceedings of the National Academy of Sciences, 76(1), 106-110. DOI: 10.1073/pnas.76.1.106.

Sahoo A, Das PK, Dasu VV, Patra S (2024). Insulin evolution: A holistic view of recombinant production advancements. International Journal of Biological Macromolecules, 277, 133951. DOI: 10.1016/j.ijbiomac.2024.133951.

Kaki SS, Prasad NBL, Chintagunta AD, Dirisala VR, Kumar N, Naidu MM, Ramesh KV (2022). Industrial Scale Production of Recombinant Human Insulin using Escherichia coli BL-21. Iranian Journal of Science and Technology, Transactions A: Science, 46(2), 373-383. DOI: 10.1007/s40995-022-01269-7.

Siew YY, Zhang W (2021). Downstream processing of recombinant human insulin and its analogues production from E. coli inclusion bodies. Bioresources and Bioprocessing, 8(1), 65. DOI: 10.1186/s40643-021-00419-w.

Konstantinov KB, Cooney CL (2015). White Paper on Continuous Bioprocessing. May 20-21, 2014 Continuous Manufacturing Symposium. Journal of Pharmaceutical Sciences, 104(3), 813-820. DOI: 10.1002/jps.24268.

Khanal O, Lenhoff AM (2021). Developments and opportunities in continuous biopharmaceutical manufacturing. mAbs, 13(1), 1903664. DOI: 10.1080/19420862.2021.1903664.

Pei S, Liu S, Luo J, Chen J, Luo H, Wu W, Chen X (2025). High-Yield Biosynthesis Process for Producing Insulin Lispro. The Protein Journal, 44(4), 363-376. DOI: 10.1007/s10930-025-10278-5.

Warikoo V, Godawat R, Brower K, Jain S, Cummings D, Simons E, Johnson T, Walther J, Yu M, Wright B, McLarty J, Karey KP, Hwang C, Zhou W, Riske F, Konstantinov K (2012). Integrated continuous production of recombinant therapeutic proteins. Biotechnology and Bioengineering, 109(12), 3018-3029. DOI: 10.1002/bit.24584.

Shin CS, Hong MS, Bae CS, Lee J (1997). Enhanced production of human mini-proinsulin in fed-batch cultures at high cell density of Escherichia coli BL21(DE3)[pET-3aT2M2]. Biotechnology Progress, 13(3), 249-257. DOI:

1021/bp970018m. 10. Jing J, Chen Y, Sheng L, Wu M (2018). Optimized production of insulin variant, a recombinant platelet aggregation inhibitor, by high cell-density fermentation of recombinant Escherichia coli. Protein Expression and Purification, 152, 7-12. DOI: 10.1016/j.pep.2018.07.001.

Kumar SR, Shukla E, Pandey G (2026). High Cell Density Fermentation Strategy for High-Level Soluble Expression of Glucagon-like Peptide-1 Analogue in Escherichia coli. Fermentation, 12(1), 53. DOI: 10.3390/fermentation12010053.

Curvers S, Linnemann J, Klauser T, Wandrey C, Takors R (2002). Recombinant Protein Production with Pichia pastoris in Continuous Fermentation - Kinetic Analysis of Growth and Product Formation. Engineering in Life Sciences, 2(8), 229-235. DOI: 10.1002/1618-2863(20020806)2:8<229::AID-ELS C229>3.0.CO;2-9.

Zhang W, Liu CP, Inan M, Meagher MM (2004). Optimization of cell density and dilution rate in Pichia pastoris continuous fermentations for production of recombinant proteins. Journal of Industrial Microbiology & Biotechnology, 31(7), 330-334. DOI: 10.1007/s10295-004-0155-4.

Looser V, Bruhlmann B, Bumbak F, Stenger C, Costa M, Camattari A, Fotiadis D, Kovar K (2015). Cultivation strategies to enhance productivity of Pichia pastoris: A review. Biotechnology Advances, 33(6 Pt 2), 1177-1193. DOI: 10.1016/j.biotechadv.2015.05.008.

Yang Z, Zhang Z (2018). Engineering strategies for enhanced production of protein and bio-products in Pichia pastoris: A review. Biotechnology Advances, 36(1), 182-195. DOI: 10.1016/j.biotechadv.2017.11.002.

Siew YY, Rai A, Pek HB, Ow DSW, Zhang W (2021). New and efficient purification process for recombinant human insulin produced in Escherichia coli. Applied Microbiology and Biotechnology, 105(24), 9137-9151. DOI: 10.1007/s00253-021-11697-x.

Borhani SG, Levine MZ, Gurramkonda C, Qu Y, Tao D, LeClair CA, Swartz JR, Rao G (2025). On-demand insulin manufacturing using cell-free systems with an "on-column" conversion approach. New Biotechnology, 89, 51-59. DOI: 10.1016/j.nbt.2025.06.002.

Zydney AL (2015). Continuous downstream processing for high value biological products: A Review. Biotechnology and Bioengineering, 113(3), 465-475. DOI: 10.1002/bit.25695.

Godawat R, Brower K, Jain S, Konstantinov K, Riske F, Warikoo V (2012). Periodic counter-current chromatography - design and operational considerations for integrated and continuous purification of proteins. Biotechnology Journal, 7(12), 1496-1508. DOI: 10.1002/biot.201200068.

Dutta AK, Tran T, Napadensky B, Teella A, Brookhart G, Ropp PA, Zhang AW, Tustian AD, Zydney AL, Shinkazh O (2015). Purification of monoclonal antibodies from clarified cell culture fluid using Protein A capture continuous countercurrent tangential chromatography. Journal of Biotechnology, 213, 54-64. DOI: 10.1016/j.jbiotec.2015.02.026.

Kateja N, Kumar D, Sethi S, Rathore AS (2018). Non-protein A purification platform for continuous processing of monoclonal antibody therapeutics. Journal of Chromatography A, 1579, 60-72. DOI: 10.1016/j.chroma.2018.10.031.

Clincke MF, Mölleryd C, Zhang Y, Lindskog E, Walsh K, Chotteau V (2013). Very high density of CHO cells in perfusion by ATF or TFF in WAVE bioreactor. Part I. Effect of the cell density on the process. Biotechnology Progress, 29(3), 754-767. DOI: 10.1002/btpr.1704.

Clincke MF, Mölleryd C, Samani PK, Lindskog E, Fäldt E, Walsh K, Chotteau V (2013). Very high density of Chinese hamster ovary cells in perfusion by alternating tangential flow or tangential flow filtration in WAVE bioreactor - part II: Applications for antibody production and cryopreservation. Biotechnology Progress, 29(3), 768-777. DOI: 10.1002/btpr.1703.

Yang O, Prabhu S, Ierapetritou M (2019). Comparison between Batch and Continuous Monoclonal Antibody Production and Economic Analysis. Industrial & Engineering Chemistry Research, 58(15), 5851-5863. DOI: 10.1021/acs.iecr.8b04717.

Croughan MS, Konstantinov KB, Cooney C (2015). The future of industrial bioprocessing: Batch or continuous? Biotechnology and Bioengineering, 112(4), 648-651. DOI: 10.1002/bit.25529.

Matanguihan C, Wu P (2022). Upstream continuous processing: recent advances in production of biopharmaceuticals and challenges in manufacturing. Current Opinion in Biotechnology, 78, 102828. DOI: 10.1016/j.copbio.2022.102828.

Downloads

Published

2026-06-27